Vun-Sin Lim, PhD

🆕Just published🆕 #LCAM25 Editorial from #JTO Editor-in-Chief Alex Adjei:

"Lung Cancer in 2025: Advances in Treatment Continue, but Access Remains Unequal"

🔗 Read the full article here: www.jto.org/article/S155...

@iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social #LCSM

Getting ready for #IASLC Asia Conference on Lung Cancer this week!

Want to know more about #JTO #JTOCRR publications or Reviewer Workshop? Happy to connect in person.

#ACLC25 @iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social #PeerReview #ScholarlyPublication

#WCLC25 It takes a village!

Thanks to all our dedicated editors, reviewers, our publisher and my editorial office teams! Thanks for the support from our authors and @iaslc.bsky.social!

@jtoonline.bsky.social @elsevierhms.bsky.social #JTO #JTOCRR

#WCLC25 Meet the Editors - Engaging Q&A session between meeting attendees and Editors-in-Chief, Dr Alex Adjei #JTO and Dr Emily Stone #JTOCRR.

@iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social #scholarlypublishing

kdvr.com/news/health/...

#JTO & #JTOCRR Editorial Reception

This annual get-together at #WCLC25 lets editors, top reviewers, the editorial office teams and publisher reconnect in person in a meaningful way in the middle of a very busy conference.

@iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social

@iaslc.bsky.social @jtoonline.bsky.social #WCLC25 #peerreview

#WCLC25 Reviewer Workshop - Here are the next generation of reviewers!

It’s heartwarming to know many attendees came here just for this workshop. A few dedicated participants attended online despite unforeseen circumstances. I’m grateful for all of you, faculty and participants.
@iaslc.bsky.social

#WCLC25 Happening now: IASLC Reviewer Workshop. Alex Adjei - “Top 10 of the do’s and dont’s as a reviewer”

@iaslc.bsky.social @jtoonline.bsky.social #JTO #JTOCFR #peerreview

#WCLC25 Our #JTO editors got many talents!

@drtomjohn.bsky.social @drsanjaypopat.bsky.social @jtoonline.bsky.social @iaslc.bsky.social

Looking forward to playing with @drsanjaypopat.bsky.social - a lot of fun rehearsing covers and @mayhemtomi tracks. Check us out tonight @iaslc.bsky.social #wclc2025

#WCLC25 WS04: Joint IASLC-CSCO-CAALC session happening now in Room 06.

Case presentations and discussions with the panelists with global perspectives.

@iaslc.bsky.social

Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction Copy number alterations of chromosome 9p, or parts thereof, impair immune response and confer immune-checkpoint therapy (ICT) resistance by direct elimination of immune-regulatory genes on this arm, n...

Read the special article at #JTO: jto.org/article/S155...

"Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction"

@jtoonline.bsky.social

Cancer Breakthrough Sparks New Vaccine Researchers at UC San Diego and their collaborators have helped answer one of the most difficult questions in oncology: why do some tumors not respond to immunotherapy?

🆕Special article by Lippman and colleagues in #JTO

📰Press release by UCSD: today.ucsd.edu/story/cancer...

@ucsdcancer.bsky.social @iaslc.bsky.social @sciencedirect.bsky.social @elsevierhms.bsky.social @jtoonline.bsky.social #LCSM

Early weight gain as a risk factor for increased maximum weight gain among NSCLC patients on lorlatinib & other ALK tyrosine kinase inhibitors - JTO Clinical and Research Reports.

#LCSM #LungCancer
www.jtocrr.org/article/S266...

✍️June #JTO Editor’s pick 3 of 4: Deuterated Osimertinib

🆓 access: www.jto.org/article/S155...

📎 Also see Deuterated Lorlatinib: www.jto.org/article/S155...
📎 Accompanying editorial: www.jto.org/article/S155...

@jtoonline.bsky.social @iaslc.bsky.social @elsevierhms.bsky.social #LCSM

🆕 #JTO Review Article from the #IASLC Basic and Translational Science Committee
🆓 access to full texts 🔗 jto.org/article/S155...

@jtoonline.bsky.social @iaslc.bsky.social @elsevierhms.bsky.social #lungcancer

🆕 #JTO Review Article from IASLC Advanced Radiation Technology subcommittee

🔗 www.jto.org/article/S155...

#OpenAccess @iaslc.bsky.social @jtoonline.bsky.social @elsevierconnect.bsky.social

Come join us in #hongkong 🇭🇰 🍜🥟🥡 for the #inaugural @myesmo.bsky.social #ESMOTATAsia25 on July 18-20, 2025! We have assembled a #stellar group of #international #faculties and #experts in #drugdevelopment to help move the field forward. Register today!

2025 President-Elect Candidates | IASLC The International Association for the Study of Lung Cancer (IASLC) is the only global network dedicated to the study and eradication of lung cancer and other thoracic malignancies.

🗳️ Vote for him to make a difference in the lung cancer sphere!

🔗 www.iaslc.org/2025-preside...

@jtoonline.bsky.social #JTO

Full support to Alex Adjei for President-Elect in 2025 #IASLC Board of Directors Election!

I have worked with him for 10+ years, inspired by his strong leadership, vision, advocacy, and dedication to patient care, research and publication, and mentoring the next generations.
@iaslc.bsky.social

@jtoonline.bsky.social @iaslc.bsky.social #JTO #sclc

Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer #SCLC : the phase I/II LUPER study

www.jto.org/article/S155...

The combination demonstrated promising efficacy and a manageable safety profile, particularly for platinum-sensitive patients, warranting further investigation.

Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON)

www.jto.org/article/S155...

These findings suggest that gut microbiota profiling could help optimize treatment strategies for NSCLC.

⏰NOW OUT‼️ #ELCC25
🔥MARIPOSA🦋: Amivantamab plus lazertinib vs osimertinib in 1L EGFRm advanced NSCLC: Final OS
🎙️Prof. James Yang
🎯OS HR 0.75 (95%CI: 0.61-0.92)
🎯Seems like extending the OS for 1️⃣2️⃣ months
✅NCT04487080
#LCSM #EGFR
@oncoalert.bsky.social
@myesmo.bsky.social
@iaslc.bsky.social

MARIPOSA final OS analysis

❇️ Significant HR 0.75
❇️ 9% 3yr benefit
❇️ Projected mOS 4 years
❇️ Longer control of CNS disease

❗️At the cost of toxicity
❗️No data on duration of toxicity
❗️PROM and QoL data important

More effective than Osimertinib
Most suitable for higher risk pts

#ELCC25

Congratulations to Keith Kerr, a long-time IASLC member, for receiving the 2025 Heine H Hansen Award at #ELCC2025 👏🏽👏🏽

TASLC President: Dr. James Chih-Hsin Yang
Workshop director: Dr. Alex Adjei
Workshop faculty members: Drs. Myung-Ju Ann, Chee Khoon Lee, Tetsuya Mitsudomi and Vun-Sin Lim
#JTO #JTOCRR #peerreview @iaslc.bsky.social